Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer

Laboratory Investigation

Volumn 75, Issue 2, 1996, Pages 263-272

  Garrigue Antar, Laure ^a   Souza, Rhonda F ^b   Vellucci, Vincent F ^a   Meltzer, Stephen J ^b   Reiss, Michael ^a  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; CONTROLLED STUDY; ESOPHAGUS CANCER; GENE EXPRESSION; GENE LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; METHYLATION; MISSENSE MUTATION; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; TREATMENT OUTCOME;

BASE SEQUENCE; CARCINOMA; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

EID: 0029762628     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bae HW, Geiser AG, Kim DH, Chung MT, Burmester JK, Sporn MB, Roberts AB, and Kim S-J (1995). Characterization of the promoter region of the human transforming growth factor-β type II receptor gene. J Biol Chem 270:29460-29468.
2. Beahrs OH, Henson DE, Hutter HVP, and Kennedy BJ (1993). Manual for staging of cancer. Philadelphia: JB Lippincott.
3. Blot WJ (1994). Esophageal cancer trends and risk factors. Semin Oncol 21:403-410.
4. Derynck R (1994). TGF-beta-receptor-mediated signaling. Trends Biochem Sci 19:548-553.
5. Fynan TM and Reiss M (1993). Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncogen 4:493-540.
6. Gardiner-Garden M and Frommer M (1987). CpG islands in vertebrate genomes. J Mol Biol 196:261-282.
7. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF, and Reiss M (1995). Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res 55:3982-3987.
8. Gerwin BI, Spillare E, Forrestier K, Lehman TA, Kispert J, Welsh JA, Pfeifer AMA, Lechner JF, Baker SJ, Vogelstein B, and Harris CC (1992). Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor β1. Proc Natl Acad Sci USA 89:2759-2763.
9. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, and Jones PA (1995). Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531-4535.
10. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261.
11. Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, Sidransky D, and Baylin SB (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530.
12. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, and Harris CC (1990). Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 87: 9958-9961.
13. Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y, McDaniel T K, Newkirk C, Resau JH, Sridhara R, Reid BJ, and Meltzer SJ (1992). Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 52:6525-6530.
14. Humphries DE, Bloom BB, Fine A, and Goldstein RH (1994). Structure and expression of the promoter for the human type Il transforming growth factor-beta receptor. Biochem Biophys Res Commun 203:1020-1027.
15. Jiang W, Kahan N, Tomira N, Zhang Y, Lu S, and Weinstein IB (1992). Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52:2980-2983.
16. Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S, and George D (1994). Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc Natl Acad Sci USA 91:6002-6006.
17. Kalkhoven E, Roelen BAJ, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJM, van der Saag PT, and van der Burg B (1995). Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Diff 6:1151-1156.
18. Ke Y, Stoner GD, Demetrick DJ, and Bennett WP (1996). Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver and breast. Proc Am Assoc Cancer Res 37:116.
19. Klimstra DS (1994). Pathologic prognostic factors in esophageal carcinoma. Semin Oncol 21:425-430.
20. INK4B through an Sp1 consensus site. J Biol Chem 270:26750-26753.
21. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, and Willson JKV (1995). Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338.
22. Meltzer SJ, Yin J, Manin B, Rhyu M-G, Cottrell J, Hudson E, Redd JL, Krasna MJ, Abraham JM, and Reid BJ (1994). Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res 54:3379-3382.
23. Myeroff LL, Parsons R, Kim S-J, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K, Bang Y-J, Lee HY, Park J-G, Lynch HT, Roberts AB, Vogelstein B, and Markowitz SD (1995). A transforming growth factor β type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55:5545-5547.
24. Okamoto A, Jiang W, Kim SJ, Spillare EA, Stoner G, Weinstein IB, and Harris CC (1994). Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line. Proc Natl Acad Sci USA 91:11570-11580.
25. Park K, Kim S-J, Bang Y-J, Park J-G, Kim NK, Roberts AB, and Sporn MB (1994). Genetic changes in the transforming growth factor β (TGFβ) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to TGFβ. Proc Natl Acad Sci USA 91:8772-8776.
26. Parsons R, Myeroff LL, Liu B, Willson JKV, Markowitz SD, Kinzler KW, and Vogelstein B (1995). Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res 55:5548-5550.
27. Reiss M, Vellucci VF, and Zhou Z-L (1993). Loss of sensitivity to the anti-proliferative effect of transforming growth factor-β1 associated with the expression of mutant p53 tumor suppressor gene in murine keratinocytes. Cancer Res 53:899-904.
28. Roberts AB and Sporn MB (1993). Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 8:1-9.
29. Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang X-F, and Brattain MG (1994). Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269:26449-26455.